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INTERVIEW Open Access
From aging worms to the influence of the
microbiota: an interview with David Weinkove
David Weinkove
David Weinkove did his undergraduate degree at
Cambridge, then a PhD at University College London
with Mike Waterfield and Sally Leevers. His first post-
doctoral position was with Ronald Plasterk at the
Hubrecht Laboratory in the Netherlands, followed by
another with Nullin Divecha at the Netherlands Cancer
Institute. He then went to David Gems’ lab at University
College London, where he worked on the study of aging
in Caenorhabditis elegans, before moving to Durham
University in 2008.
We spoke to him about the paper he published
with David Gems in BMC Biology [1] when an
apparently straightforward experiment on C. elegans
longevity took a surprising turn that refocused
Weinkove on the Escherichia coli that the worms
feed on and the influence of the microbiota on
health and longevity.
The research that you’ve published with us in
BMC Biology started off with a screen for genes
that affect longevity in the classic longevity
animal, the C. elegans nematode worm, but
unexpectedly led you into insights into the effect
of the microbiome. How did that happen?
I was in David Gems’ lab, where we were looking for genes
that influence life span. A very nice thing that you can do
with C. elegans is to knock out genes simply by feeding
them E. coli that have a plasmid in them that contains
RNAi for the worm gene you’re interested in. E. coli is the
standard diet for C. elegans in the lab - growing C. elegans
on lab strains of E. coli is just something that Sydney
Brenner decided to do when he started working on C.
elegans in the late sixties. He just did it because it was
convenient, and 40 years later, C. elegans biologists all over
the world do exactly the same thing with exactly the same
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strains. So I was feeding worms E. coli that was knocking
out some genes that we thought might be involved in
lifespan.
And with one of these E. coli strains, which we
expected to make the worms shorter-lived, the worms
actually lived dramatically longer. In biology, you don’t
ignore results like that. If you see a big effect, you go
after it. For quite a long time I thought this E. coli was
knocking out a particular C. elegans gene. And then one
day, I just noticed that there was a very subtle difference
in color between the strain I was using and the control
strain. I showed it to a PhD student, and he couldn’t see
the difference. But because I had been looking at this E.
coli strain for such a long time, I could see there was a
slight difference. So I thought well maybe this is not to
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do with the worm gene, maybe it’s something that has
happened to this E. coli strain. So I got rid of the plas-
mid DNA that was knocking out the gene from C.
elegans and found that this particular E. coli strain still
made the worms live longer. It was nothing to do with
knocking out the worm gene - something had happened
to the E. coli strain. That made us think there was some
sort of spontaneous mutation that occurred in this E.
coli strain and made the worms live longer. We found
what it was when we found that these E. coli grew poorly
on medium lacking glycine, and it turned out that the
gene that was disrupted was a metabolic gene involved
in making aromatic compounds. And by adding back
different compounds, we pinned it down to PABA,
which is the precursor of folates, a broad term which in-
cludes folic acid. Folates are essential for life.
And in fact are added to our diet in various ways
Yes, in the US they supplement flour with it. In the UK
we have it in cereals and margarine. It’s important. The
supplementation is done to prevent neural tube defects,
but it’s actually very important generally for growth. The
funny thing is animals don’t make it. So we need to get
it either from our diet or from our microbes. Microbes
in the gut make a lot of folic acid, and that would be the
main source of folates for C. elegans.
So, I moved to set up my own lab in Durham. We
started using some inhibitors of folate synthesis to try
and get the same effect as the E. coli mutant. The sul-
fonamide drugs inhibit folate synthesis in microbes, and
my PhD student found that the more sulfonamide you
add, the longer the worms live. You can do this just by
using a drug. That’s how we got to the discovery that we
reported in our BMC Biology paper - it was just an acci-
dental discovery that led to finding that inhibiting folate
synthesis in the microbes makes the worms live longer.
The obvious question is - if sulfonamide drugs do
this to worms, what do they do in mammals?
Well that was something interesting that we found
out when we went to the Patent Office, because
Durham University tries to make sure that we protect
our intellectual property. The Patent Office found a
paper published in 1958, and written in German, from
Bayer, which is the German company that originally
discovered sulfonamides. They had been trying to
see if the drugs were useful in treating cancer, and
they made the incidental observation that mice and
rats and even dogs that were given sulfonamides lived
longer [2].
Now that was a little bit anecdotal and it needed to be
followed up, but it was quite an interesting observation.
And much more recently, Jeffrey Gordon’s lab, where
they are very interested in the microbiome, looked at
changes in microbial genes across all microbes in the
human gut and how they change at different ages [3].
The gene class that they picked up - I think it was the
strongest one - and that they put in their paper, was to
do with folate synthesis. This is really more to do with
development than with aging. Before two years old, mi-
crobial folate synthesis genes are highly represented.
After two, the folate synthesis genes go down and you
get folate salvage genes. What we think is that a lot of
microbes are making a lot of folate and that’s why some
other microbes need to salvage it - maybe this indicates
that too much folate is bad for you.
When you say too much, too much for what?
Too much for growth. Folate works as an enzyme. It’s
needed for biosynthesis - but it’s not actually consumed
in the biosynthesis, it works as a coenzyme. You only
need a very small amount of folate. The really fascinat-
ing thing was, if you treat a microbe with a sulfonamide
you’d think you’d kill it off, but we don’t. We don’t see
any effect on the growth of bacteria with the sulfon-
amides. When you measure the folate levels, they come
right down, but there’s still enough folate for the bacteria
to grow fine. They’re obviously making much more than
they need in our system. Then there’s some other old
data that show that quite a lot of microbes make and ex-
crete folate. So in terms of what’s going on - now, mi-
crobes don’t do anything for no reason. There must be a
reason for all this folate synthesis - we just don’t under-
stand what it is. We think they’re making more than
they need, but we haven’t worked out if that’s actually
happening in vivo. We have to try and look at real mi-
crobes, microbes from the mammalian gut - is this really
happening there?
So should we all be concluding that too much
folate is bad for us for reasons we don’t
understand?
Well no, this is the interesting thing. More recently
we’ve found that even though we treat the microbes with
sulfonamides so they get less folate and there’s less folate
in the worm, it’s not the decreased folate in the worm
that’s making the worms live longer. We know this be-
cause we can supplement with folinic acid, which is a
more natural supplement than the stuff that’s used in
supplements for cereals and other foods. A small dose of
folinic acid can directly restore the folates in the worm
to high levels without affecting the gut bacteria, and that
manipulation doesn’t affect the lifespan effect. So it
could be that folates are good for you in your body, but
having too much folate in your gut microbes might
cause the gut microbes to do something that’s not very
good for you.
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So does this mean we need to look at what
people have called the holo-biome - not just the
organism, but all the microorganisms associated
with it - in order to understand the effects of any
metabolic interference - is that the bottom line?
I think that’s important, yes. We’ve co-evolved with mi-
crobes. That’s the whole system - the microbes’ inter-
action with each other and with the host. Whether it’s a
metabolic thing, I’m not sure. It seems that there is an
effect of folates - something that’s going on in the mi-
crobes that are making too much folate - that has an ef-
fect on the host. And that raises an interesting point
about the supplements. We were confused for a long
time because when we gave folic acid, which is the trad-
itional oxidized folic acid that you find in supplements,
we found that we did reverse the lifespan effect. But
then we found that what happens with that folic acid is
that there’s a breakdown product that can be taken up
and used by E. coli. Now that has some ramifications be-
cause when we’re taking our folic acid supplements,
we’re going to be absorbing some of it, but some is
going to be broken down and absorbed by our microbes.
So although some microbes take up the folic acid
directly, E. coli and many others take up the breakdown
product. So maybe it’s better to use different sorts of
supplements than folic acid.
Are you suggesting that any sort of supplement
or drugs that we might take, we need to
understand what they’re doing to the gut
microbiota before we can understand what
they’re likely to do to us?
I think there’s a very high chance that any drug or
supplement that we take will be metabolized by gut mi-
crobes, and will have an effect on us potentially through
gut microbes.
So what is your own lab pursuing now? Are you
still looking at longevity or has this changed the
focus of your research?
We are still looking at longevity. We still need to under-
stand what it is about excess folate in the microbes that’s
effectively limiting the lifespan, so that when we take it
out the worms live longer and are healthier. As I said,
this gene was found by accident. Maybe there are other
genes out there. We’ve started doing screens for other
genes in E. coli that might also affect lifespan. But the
folic acid effect is a really robust thing. It has stood the
test of a lot of experiments in our lab. We’re trying to
see if this is applicable in mammalian systems, if it’s ap-
plicable in other forms of microbes - not just the lab
strain that Sydney Brenner decided to use - but actually
in microbes that have been implicated in disease or mi-
crobes straight out of the human gut.
So it’s driven you up the phylogenetic tree to
mammals and out from lab E. coli into the rest of
the microbiome. That seems a very large step to
have taken
It’s interesting because my background is working with
C. elegans but now I’m working with E. coli a lot more.
But at the same time, as you say, it has more relevance
potentially to human health than perhaps some of the
more direct C. elegans work.
So, for example, treating microbes with antibiotics is
not a good idea. You don’t want to kill off your mi-
crobes, you need to keep the balance of your microbiota.
So what’s interesting about our experimental interven-
tion is that it doesn’t seem to affect the growth of the
microbes. So it gives us hope that it might be useful. All
the drugs developed against microbes have been about
killing the microbe. Actually maybe the new class of
drug is about modulating the metabolism of the mi-
crobes without killing them and that’s the way to go.
That’s what we’re trying to think about doing. Because
you can’t actually give someone a sulfonamide, like
SMX, long-term. It accumulates in the thyroid and
causes problems. What we want is a drug that doesn’t
go into the body, stays in the gut, affects the microbes,
doesn’t really harm the microbes, just tweaks their me-
tabolism. That’s what you want I think. Otherwise you
get resistance and loss of diversity. It might be that nat-
ural foods tweak microbial metabolism already. Green
tea or something like that. One thing that the microbial
field is going away from - it’s not so much about which
species of bacteria you have, but which metabolic path-
ways are active. That gives us hope that just working
with this single strain of a single microbe might still be
useful because you’re finding pathways that are also in
other microbes. So the focus is moving towards metabol-
ism in the microbes, rather than just what one species
does and what another species does.
So really I was wrong when I said you’re moving
up the phylogenetic tree - you’re really moving
down, from C. elegans to E. coli
Well, yes. You know, we only know what about half the
genes in E. coli are doing - 1,700 out of 4,000 are of un-
known function, probably to do with interactions with
the environment. Worms are really great for their con-
venience and ease of breeding, and they’re inexpensive
to maintain - a great austerity organism. But now I see
them more as a biosensor for what E. coli is doing.
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